{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:05:35Z","timestamp":1794549935161,"version":"4.9.1"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872687"],"award-info":[{"award-number":["81872687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573222"],"award-info":[{"award-number":["81573222"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.cytogfr.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T13:13:32Z","timestamp":1544620412000},"page":"9-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Interleukin-13: A promising therapeutic target for autoimmune disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Yan-Mei","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8624-6500","authenticated-orcid":false,"given":"Jing","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Xue","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Qing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-4774","authenticated-orcid":false,"given":"Song Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Feng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","article-title":"Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?","volume":"11","author":"Costenbader","year":"2012","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0010","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ni.1899","article-title":"Effector T cell plasticity: flexibility in the face of changing circumstances","volume":"11","author":"Murphy","year":"2010","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytogfr.2013.09.001","article-title":"Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases","volume":"24","author":"Pan","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib0020","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.4049\/jimmunol.172.9.5213","article-title":"Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10","volume":"172","author":"Zheng","year":"2004","journal-title":"J. Immunol. (Baltimore, Md. : 1950)"},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib0025","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/all.13438","article-title":"ILC2 frequency and activity are inhibited by glucocorticoid treatment via STAT pathway in patients with asthma","volume":"73","author":"Yu","year":"2018","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0030","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s10067-010-1510-7","article-title":"The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients","volume":"29","author":"Ma","year":"2010","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/cmi.2012.18","article-title":"The development and function of follicular helper T cells in immune responses","volume":"9","author":"Chen","year":"2012","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.autrev.2013.12.004","article-title":"Th17 and regulatory T cell balance in autoimmune and inflammatory diseases","volume":"13","author":"Noack","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0045","first-page":"94","article-title":"Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?","volume":"2","author":"Zheng","year":"2013","journal-title":"Am. J. Clin. Exp. Immunol."},{"issue":"25","key":"10.1016\/j.cytogfr.2018.12.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1604","article-title":"Type 2 immunity: expanding our view","volume":"3","author":"Lloyd","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmed.2017.00139","article-title":"Interleukin-13 in asthma and other eosinophilic disorders","volume":"4","author":"Doran","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pupt.2017.05.007","article-title":"IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies","volume":"45","author":"Passalacqua","year":"2017","journal-title":"Pulmonary Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/cmi.2015.50","article-title":"Interleukin-13 interferes with activation-induced t-cell apoptosis by repressing p53 expression","volume":"13","author":"Yang","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0070","doi-asserted-by":"crossref","first-page":"36002","DOI":"10.1038\/srep36002","article-title":"IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0075","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2010.09.047","article-title":"Colitis and intestinal inflammation in IL10-\/- mice results from IL-13Ralpha2-mediated attenuation of IL-13 activity","volume":"140","author":"Wilson","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4049\/jimmunol.1102216","article-title":"IL-13 regulates Th17 secretion of IL-17A in an IL-10-dependent manner","volume":"188","author":"Newcomb","year":"2012","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2018.12.001_bib0085","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4049\/jimmunol.1700372","article-title":"IL-4\/IL-13 heteroreceptor influences Th17 cell conversion and sensitivity to regulatory T cell suppression to restrain experimental allergic encephalomyelitis","volume":"199","author":"Barik","year":"2017","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib0090","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/eji.201142227","article-title":"IL-13-producing Th1 and Th17 cells characterize adaptive responses to both self and foreign antigens","volume":"42","author":"Gallo","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cyto.2015.05.018","article-title":"Strategies targeting the IL-4\/IL-13 axes in disease","volume":"75","author":"May","year":"2015","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: IL-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0105","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.4049\/jimmunol.178.12.7550","article-title":"Agonist-driven development of CD4+CD25+Foxp3+ regulatory T cells requires a second signal mediated by Stat6","volume":"178","author":"Sanchez-Guajardo","year":"2007","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0110","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.1300486","article-title":"STAT6 controls the number of regulatory T cells in vivo, thereby regulating allergic lung inflammation","volume":"191","author":"Dorsey","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0115","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22010134","article-title":"Therapeutic potential of targeting the Th17\/Treg axis in autoimmune disorders","volume":"22","author":"Fasching","year":"2017","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/biof.1117","article-title":"Role of interleukin-13 in fibrosis, particularly systemic sclerosis","volume":"39","author":"O\u2019Reilly","year":"2013","journal-title":"BioFactors"},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.09.019","article-title":"IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy","volume":"137","author":"Lee","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1172\/JCI200522818","article-title":"IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation","volume":"115","author":"Vladich","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"6417","key":"10.1016\/j.cytogfr.2018.12.001_bib0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","article-title":"Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses","volume":"362","author":"Minty","year":"1993","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cytogfr.2018.12.001_bib0140","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/j.1460-2075.1993.tb05927.x","article-title":"Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction","volume":"12","author":"Zurawski","year":"1993","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","article-title":"T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production","volume":"75","author":"Zhu","year":"2015","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000063145","article-title":"T cells and mast cells as a major source of interleukin-13 in atopic dermatitis","volume":"205","author":"Obara","year":"2002","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0160","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1128\/IAI.74.3.1471-1479.2006","article-title":"Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity","volume":"74","author":"Reiman","year":"2006","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bcmd.2015.01.007","article-title":"Granulocyte-macrophage colony-stimulating factor primes interleukin-13 production by macrophages via protease-activated receptor-2","volume":"54","author":"Aoki","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0170","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/gutjnl-2012-303461","article-title":"Interleukin 13 and its role in gut defence and inflammation","volume":"61","author":"Mannon","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and structural basis of cytokine receptor pleiotropy in the Interleukin-4\/13 system","volume":"132","author":"LaPorte","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0185","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.90430.2008","article-title":"Immune-mediated signaling in intestinal goblet cells via PI3-kinase- and AKT-dependent pathways","volume":"295","author":"Wang","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0190","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.4049\/jimmunol.176.12.7495","article-title":"Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling","volume":"176","author":"Daines","year":"2006","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0195","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.4049\/jimmunol.179.10.6429","article-title":"Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses","volume":"179","author":"Khodoun","year":"2007","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0200","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/jmr.2150","article-title":"Equilibrium and kinetic analysis of human interleukin-13 and IL-13 receptor alpha-2 complex formation","volume":"25","author":"Lacy","year":"2012","journal-title":"J. Mol. Recognit."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4049\/jimmunol.1301761","article-title":"Endogenously expressed IL-13Ralpha2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts","volume":"193","author":"Chandriani","year":"2014","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0210","doi-asserted-by":"crossref","first-page":"10387","DOI":"10.1074\/jbc.M108109200","article-title":"A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha -2 and their rapid mobilization by interferon-gamma","volume":"277","author":"Daines","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis","volume":"12","author":"Fichtner-Feigl","year":"2006","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0220","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ijc.26366","article-title":"IL-13 regulates cancer invasion and metastasis through IL-13R\u03b12 via ERK\/AP-1 pathway in mouse model of human ovarian cancer","volume":"131","author":"Fujisawa","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0225","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/all.13424","article-title":"Role of IL-13R\u03b12 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa","volume":"73","author":"Liu","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0230","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ibd.21133","article-title":"Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway","volume":"16","author":"Mandal","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0235","article-title":"Tricellulin is regulated via interleukin-13-receptor alpha2, affects macromolecule uptake, and is decreased in ulcerative colitis","author":"Krug","year":"2017","journal-title":"Mucosal Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cyto.2015.05.008","article-title":"The differential expression of IL-4 and IL-13 and its impact on type-2 immunity","volume":"75","author":"Bao","year":"2015","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0245","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000376579","article-title":"The interleukin-13 receptor-\u03b11 Chain Is essential for induction of the alternative macrophage activation pathway by IL-13 but not IL-4","volume":"7","author":"Sheikh","year":"2015","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","article-title":"Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease","volume":"31","author":"Van Dyken","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0255","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/CIRCHEARTFAILURE.113.001020","article-title":"Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction","volume":"7","author":"Hofmann","year":"2014","journal-title":"Circul. Heart failure"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0091-6749(98)70080-6","article-title":"The role of IL-13 and its receptor in allergy and inflammatory responses","volume":"102","author":"d.V","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"issue":"25","key":"10.1016\/j.cytogfr.2018.12.001_bib0265","doi-asserted-by":"crossref","first-page":"17937","DOI":"10.18632\/oncotarget.24788","article-title":"Phytochemicals as modulators of M1-M2 macrophages in inflammation","volume":"9","author":"Saqib","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2169\/internalmedicine.36.179","article-title":"Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis","volume":"36","author":"Horie","year":"1997","journal-title":"Int. Med. (Tokyo, Japan)"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0275","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.immunol.21.120601.141142","article-title":"IL-13 effector functions","volume":"21","author":"Wynn","year":"2003","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0280","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.4049\/jimmunol.164.5.2585","article-title":"Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent","volume":"164","author":"Fallon","year":"2000","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib0285","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.4049\/jimmunol.0803868","article-title":"A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production","volume":"182","author":"Newcomb","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0290","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2010.11.043","article-title":"Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production","volume":"127","author":"Newcomb","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0295","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jaci.2016.04.037","article-title":"IL-17A enhances IL-13 activity by enhancing IL-13-induced signal transducer and activator of transcription 6 activation","volume":"139","author":"Hall","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3-4","key":"10.1016\/j.cytogfr.2018.12.001_bib0300","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00011-015-0806-0","article-title":"Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis","volume":"64","author":"Huang","year":"2015","journal-title":"Inflamm. Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0305","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s10067-012-1962-z","article-title":"Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts","volume":"31","author":"Brown","year":"2012","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2018.12.001_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041994","article-title":"Periostin facilitates skin sclerosis via PI3K\/Akt dependent mechanism in a mouse model of scleroderma","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1016\/j.cytogfr.2018.12.001_bib0315","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/mi.2008.40","article-title":"The role of IL-13 and NK T cells in experimental and human ulcerative colitis","volume":"1","author":"Fuss","year":"2008","journal-title":"Mucosal Immunol."},{"issue":"16","key":"10.1016\/j.cytogfr.2018.12.001_bib0320","doi-asserted-by":"crossref","first-page":"12037","DOI":"10.1074\/jbc.M109.064808","article-title":"Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity","volume":"285","author":"Weber","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1113\/JP272492","article-title":"Insights into the pathophysiology of ulcerative colitis: interleukin-13 modulates STAT6 and p38 MAPK activity in the colon epithelial sodium channel","volume":"595","author":"Sroufe","year":"2017","journal-title":"J. Physiol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0330","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4161\/isl.24249","article-title":"Differential effects of interleukin-13 and interleukin-6 on Jak\/STAT signaling and cell viability in pancreatic \u03b2-cells","volume":"5","author":"Russell","year":"2013","journal-title":"Islets"},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0335","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/art.22823","article-title":"In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis","volume":"56","author":"Haas","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"1-2","key":"10.1016\/j.cytogfr.2018.12.001_bib0340","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.molimm.2011.08.012","article-title":"Contribution of IL-13 to early exocrinopathy in Id3-\/- mice","volume":"49","author":"Mahlios","year":"2011","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0345","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1172\/JCI78085","article-title":"Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity","volume":"125","author":"Burkett","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0350","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.autrev.2014.08.019","article-title":"Th17 cells in inflammation and autoimmunity","volume":"13","author":"Singh","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcp.2017.06.136","article-title":"Sodium butyrate regulates Th17\/Treg cell balance to ameliorate uveitis via the Nrf2\/HO-1 pathway","volume":"142","author":"Chen","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0360","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fimmu.2018.01662","article-title":"Apremilast ameliorates experimental arthritis via suppression of Th1 and Th17 cells and enhancement of CD4(+)Foxp3(+) regulatory T cells differentiation","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0365","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2017.09.034","article-title":"Association of interleukin 13 gene polymorphisms and plasma IL 13 level with risk of systemic lupus erythematosus","volume":"104","author":"Wang","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0370","first-page":"213","article-title":"Interleukin-13 in autoimmune rheumatic diseases: relationship withthe autoantibody profile","volume":"20","author":"Spadaro","year":"2002","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0375","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar3295","article-title":"Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis","volume":"13","author":"Takei","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0380","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.1780391012","article-title":"The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis","volume":"39","author":"Isom\u00e4ki","year":"1996","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0385","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"McInnes","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0390","first-page":"454","article-title":"High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity","volume":"29","author":"Tokayer","year":"2002","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0395","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jid.2016.11.037","article-title":"Skin-resident effector memory CD8+CD28- T cells exhibit a profibrotic phenotype in patients with systemic sclerosis","volume":"137","author":"Li","year":"2017","journal-title":"J. Investig. Dermatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0400","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.24432","article-title":"Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis","volume":"60","author":"Fuschiotti","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10067-002-0684-z","article-title":"Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities","volume":"22","author":"Riccieri","year":"2003","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0410","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000082331","article-title":"Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma","volume":"135","author":"Matsushita","year":"2004","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0420","first-page":"1345","article-title":"Investigation of inflammatory activity in ulcerative colitis","volume":"55","author":"Boldeanu","year":"2014","journal-title":"Rom J. Morphol. Embryol."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0425","first-page":"5498","article-title":"Serum IL-17 and IL-6 increased accompany with TGF-\u03b2 and IL-13 respectively in ulcerative colitis patients","volume":"7","author":"Feng","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0430","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ibd.22865","article-title":"Role of serum cytokine profile in ulcerative colitis assessment","volume":"18","author":"Rodriguez-Peralvarez","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0435","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.diabres.2013.01.014","article-title":"Altered immune profile from pre-diabetes to manifestation of type 1 diabetes","volume":"100","author":"Ryden","year":"2013","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0440","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.2337\/db15-1350","article-title":"Interleukin-13 pathway alterations impair invariant natural killer T-cell-mediated regulation of effector T cells in type 1 diabetes","volume":"65","author":"Usero","year":"2016","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0445","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2012.208","article-title":"Global trends, potential mechanisms and early detection of organ damage in SLE","volume":"9","author":"Mak","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0450","first-page":"171","article-title":"An update on pathogenesis of systemic lupus erythematosus","volume":"8","author":"Ahmadpoor","year":"2014","journal-title":"Iran J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0455","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.autrev.2014.10.003","article-title":"A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients","volume":"14","author":"Yaniv","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0460","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2016.06.010","article-title":"Immunomodulators in SLE: clinical evidence and immunologic actions","volume":"74","author":"Durcan","year":"2016","journal-title":"J. Autoimmun."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0465","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0470","first-page":"360","article-title":"Determination of serum interleukin-13 and nerve growth factor in patients with systemic lupus erythematosus and clinical significance","volume":"25","author":"Xu","year":"2005","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0475","first-page":"411","article-title":"Serum and urinary cytokine levels of SLE patients","volume":"67","author":"Brugos","year":"2012","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0480","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5114\/ceji.2014.45113","article-title":"Use of laser microdissection in the analysis of renal-infiltrating T cells in murine lupus","volume":"39","author":"Guo","year":"2014","journal-title":"Central-Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0485","first-page":"1022","article-title":"Elevated interleukin-13 in patients with active lupus nephritis","volume":"114","author":"Chen","year":"2001","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0490","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.06.020","article-title":"The critical role of epigenetics in systemic lupus erythematosus and autoimmunity","volume":"74","author":"Long","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0495","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/931018","article-title":"Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus","volume":"2010","author":"Zhao","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0500","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0014-5793(94)80601-2","article-title":"Interleukin-13 stimulates interleukin-6 production by human keratinocytes similarity with interleukin-4","volume":"343","author":"Derocq","year":"1994","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0505","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1073\/pnas.90.8.3730","article-title":"Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells","volume":"90","author":"Punnonen J","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0510","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni.3326","article-title":"Self-reactive IgE exacerbates interferon responses associated with autoimmunity","volume":"17","author":"Henault","year":"2016","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0515","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.autrev.2017.11.027","article-title":"IgE in lupus pathogenesis: friends or foes?","volume":"17","author":"Augusto","year":"2018","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0520","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0525","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/951210","article-title":"Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice","volume":"2010","author":"Zhou","year":"2010","journal-title":"Med. Inflamm."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0530","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0535","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cyto.2015.08.260","article-title":"The role of cytokines in the pathogenesis of rheumatoid arthritis--practical and potential application of cytokines as biomarkers and targets of personalized therapy","volume":"76","author":"Brzustewicz","year":"2015","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0540","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jbspin.2010.08.017","article-title":"Cell and cytokine imbalances in rheumatoid synovitis","volume":"78","author":"Boissier","year":"2011","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0545","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1756-185X.2011.01654.x","article-title":"Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients","volume":"15","author":"Higgs BW","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0550","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00296-017-3774-6","article-title":"Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis","author":"Azizieh","year":"2017","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0555","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.10776","article-title":"Cytokine profile of the rheumatoid nodule suggests that it is a Th1 granuloma","volume":"48","author":"Hessian","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0560","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3109135","article-title":"The relationship of cytokines IL-13 and IL-17 with autoantibodies profile in early rheumatoid arthritis","volume":"2016","author":"Silosi","year":"2016","journal-title":"J. Immunol. Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0565","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar2454","article-title":"Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis","volume":"10","author":"Marinou","year":"2008","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0570","article-title":"Correlation between IL-3 and IL-13 gene polymorphisms in Chinese patients and rheumatoid arthritis","volume":"15","author":"Wang","year":"2016","journal-title":"Genet. Mol. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0575","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/iji.12065","article-title":"Relation of IL-6, IL-13 and IL-15 gene polymorphisms to the rheumatoid factors, anti-CCP and other measures of rheumatoid arthritis activity","volume":"41","author":"Pavkova Goldbergova","year":"2014","journal-title":"Int. J. Immunogenet."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0580","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.4049\/jimmunol.167.10.6015","article-title":"Enhancing effect of IL-1, IL-17, and TNF-\u03b1 on macrophage inflammatory protein-3\u03b1 production in rheumatoid arthritis: regulation by soluble receptors and th2 cytokines","volume":"167","author":"Chabaud","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0585","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s002960000074","article-title":"Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium","volume":"20","author":"Morita","year":"2001","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0590","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.1038\/ncomms11596","article-title":"Th2 and eosinophil responses suppress inflammatory arthritis","volume":"7","author":"Chen","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0595","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","author":"Chen","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0600","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/10430340252792512","article-title":"Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis","volume":"13","author":"Woods","year":"2002","journal-title":"Hum Gene Ther."},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0605","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.4049\/jimmunol.165.5.2755","article-title":"Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium","volume":"165","author":"Woods","year":"2000","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0610","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.intimp.2014.08.024","article-title":"The role of prostaglandin E2 receptor signaling of dendritic cells in rheumatoid arthritis","volume":"23","author":"Jia","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0615","doi-asserted-by":"crossref","DOI":"10.1186\/ar1502","article-title":"Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation","volume":"7","author":"Nabbe","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0620","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0002-9440(10)63701-7","article-title":"FcgammaRI up-regulation induced by local adenoviral-mediated interferon-gamma production aggravates chondrocyte death during immune complex-mediated arthritis","volume":"163","author":"Nabbe","year":"2003","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0625","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1136\/ard.2004.034405","article-title":"Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences","volume":"64","author":"Radstake","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0630","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jcb.10531","article-title":"IL-13 regulates vascular cell adhesion molecule-1 expression in human osteoblasts","volume":"89","author":"Rifas","year":"2003","journal-title":"J. Cell. Biochem."},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0635","first-page":"2144","article-title":"Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis","volume":"34","author":"Hashimoto","year":"2007","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0640","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.4049\/jimmunol.166.4.2775","article-title":"Il-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis","volume":"166","author":"Relic B","year":"2001","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2009.02.002","article-title":"Angiogenesis and its targeting in rheumatoid arthritis","volume":"51","author":"Szekanecz","year":"2009","journal-title":"Vasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0650","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12026-017-8926-y","article-title":"Pathogenesis of systemic sclerosis-current concept and emerging treatments","volume":"65","author":"Furue","year":"2017","journal-title":"Immunol. Res."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0655","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1073\/pnas.0700021104","article-title":"Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13","volume":"104","author":"Aliprantis","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0660","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.0022-202X.2005.23730.x","article-title":"CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response","volume":"124","author":"Shen Y","year":"2005","journal-title":"J. Investig. Dermatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2018.12.001_bib0665","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1002\/art.24958","article-title":"Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1\/Th2 cytokines","volume":"60","author":"Gourh","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0670","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0675","first-page":"328","article-title":"Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis","volume":"24","author":"Hasegawa","year":"1997","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0680","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3899\/jrheum.110235","article-title":"Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression","volume":"39","author":"Broen","year":"2012","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0685","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00251-006-0135-0","article-title":"Evaluation of interleukin 13 polymorphisms in systemic sclerosis","volume":"58","author":"Granel","year":"2006","journal-title":"Immunogenetics"},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0690","first-page":"2015","article-title":"IL13RA2 gene polymorphisms are associated with systemic sclerosis","volume":"33","author":"Granel","year":"2006","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0695","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ajpath.2011.11.024","article-title":"Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets","volume":"180","author":"Greenblatt","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0700","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.bor.0000434672.77891.41","article-title":"What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?","volume":"25","author":"Assassi","year":"2013","journal-title":"Curr. Opin. Rheumatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0705","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1084\/jem.194.6.809","article-title":"Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1)","volume":"194","author":"Lee CG","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0710","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.4049\/jimmunol.173.6.4020","article-title":"IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent","volume":"173","author":"Kaviratne M","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0715","doi-asserted-by":"crossref","first-page":"25066","DOI":"10.1038\/srep25066","article-title":"IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics","volume":"6","author":"O\u2019Reilly","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0720","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cei.13045","article-title":"Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor alpha in normal and scleroderma dermal fibroblasts through protein kinase B\/Akt","volume":"191","author":"Brown Lobbins","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2018.12.001_bib0725","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.4049\/jimmunol.171.7.3550","article-title":"Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13","volume":"171","author":"Wynes","year":"2003","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0730","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.jid.5700090","article-title":"Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase\/Akt and the protein kinase C signaling pathways","volume":"126","author":"Jinnin","year":"2006","journal-title":"J. Investig. Dermatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0735","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.30647","article-title":"Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3","volume":"64","author":"Brissett","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"23","key":"10.1016\/j.cytogfr.2018.12.001_bib0740","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1007\/s00018-017-2648-0","article-title":"Periostin in inflammation and allergy","volume":"74","author":"Izuhara","year":"2017","journal-title":"Cell. Mol. Life Sci.: CMLS"},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0745","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The immune pathogenesis of scleroderma: context is everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib0750","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0755","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/art.37706","article-title":"Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0760","first-page":"892","article-title":"Increased CD226 expression on CD8+ T cells is associated with upregulated cytokine production and endothelial cell injury in patients with systemic sclerosis","volume":"195","author":"Tsukamoto","year":"2015","journal-title":"J. Immunol. (Baltimore, Md. : 1950)"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0765","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","article-title":"Role of IL-13 in systemic sclerosis","volume":"56","author":"Fuschiotti","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0770","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/art.30489","article-title":"GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production","volume":"63","author":"Medsger","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000126058","article-title":"Downregulation of IL-13 gene transcription by T-bet in human T cells","author":"Suzuki","year":"2008","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0780","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2017.10.029","article-title":"14-3-3z sequesters cytosolic T-bet, up-regulating IL-13 in Tc2 and scleroderma CD8+ lymphocytes","volume":"142","author":"Cascio","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0785","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-015-0708-0","article-title":"Transforming growth factor-beta increases interleukin-13 synthesis via GATA-3 transcription factor in T-lymphocytes from patients with systemic sclerosis","volume":"17","author":"Baraut","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0790","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/annrheumdis-2012-202476","article-title":"Activation of pregnane X receptor inhibits experimental dermal fibrosis","volume":"72","author":"Beyer","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0795","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.4049\/jimmunol.1502482","article-title":"Niclosamide prevents systemic sclerosis in a reactive oxygen species-induced mouse model","volume":"197","author":"Morin","year":"2016","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib0800","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/jid.2015.174","article-title":"Inhibition of EGFR tyrosine kinase by erlotinib prevents sclerodermatous graft-versus-host disease in a mouse model","volume":"135","author":"Morin","year":"2015","journal-title":"J. Investig. Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0805","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/gutjnl-2013-305671","article-title":"IL-13Ralpha2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis","volume":"63","author":"Fuss","year":"2014","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib0810","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1074-7613(02)00453-3","article-title":"Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells","volume":"17","author":"Heller","year":"2002","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0815","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/gut.2010.226860","article-title":"Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production","volume":"60","author":"Mannon","year":"2011","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cytogfr.2018.12.001_bib0820","first-page":"e1177","article-title":"Crohn\u2019s Disease and Ulcerative Colitis Show Unique Cytokine Profiles","volume":"9","author":"Nemeth","year":"2017","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0825","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/eji.201343524","article-title":"Absence of a role for interleukin-13 in inflammatory bowel disease","volume":"44","author":"Biancheri","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0830","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2017.01.016","article-title":"Mucosal expression of type 2 and type 17 immune response genes distinguishes ulcerative colitis from colon-only crohn\u2019s disease in treatment-naive pediatric patients","volume":"152","author":"Rosen","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0835","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study","volume":"64","author":"Reinisch W","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0840","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1684\/ecn.2013.0343","article-title":"Expression of inflammatory genes in the colon of ulcerative colitis patients varies with activity both at the mRNA and protein level","volume":"24","author":"Verma","year":"2013","journal-title":"Eur. Cytokine Netw."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0845","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/gutjnl-2015-309464","article-title":"Failure of interleukin 13 blockade in ulcerative colitis","volume":"64","author":"Tilg H","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0850","doi-asserted-by":"crossref","DOI":"10.3390\/genes9020085","article-title":"MicroRNA-31 and MicroRNA-155 are overexpressed in ulcerative colitis and regulate IL-13 signaling by targeting interleukin 13 receptor alpha-1","volume":"9","author":"Gwiggner","year":"2018","journal-title":"Genes (Basel)"},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072774","article-title":"Interleukin 13 and serotonin: linking the immune and endocrine systems in murine models of intestinal inflammation","volume":"8","author":"Shajib","year":"2013","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0860","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1089\/dna.2012.1692","article-title":"The lL-8 and IL-13 gene polymorphisms in inflammatory bowel disease and colorectal cancer","volume":"31","author":"Walczak","year":"2012","journal-title":"DNA Cell Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0865","first-page":"789","article-title":"[The significance of IL-13 gene +2044G\/A mutation in patients with inflammatory bowel disease]","volume":"145","author":"Waterman","year":"2006","journal-title":"Harefuah"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0870","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cytogfr.2018.12.001_bib0875","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1038\/mi.2008.46","article-title":"Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function","volume":"1","author":"Heller","year":"2008","journal-title":"Mucosal Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0880","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1053\/j.gastro.2011.08.040","article-title":"Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis","volume":"141","author":"Kawashima","year":"2011","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0885","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/ibd.21628","article-title":"STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction","volume":"17","author":"Rosen","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"issue":"26","key":"10.1016\/j.cytogfr.2018.12.001_bib0890","doi-asserted-by":"crossref","first-page":"10801","DOI":"10.1074\/jbc.M116.771469","article-title":"Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis","volume":"292","author":"Buzza","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.cytogfr.2018.12.001_bib0895","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1113\/JP271156","article-title":"Interleukin-13 affects the epithelial sodium channel in the intestine by coordinated modulation of STAT6 and p38 MAPK activity","volume":"593","author":"Dames","year":"2015","journal-title":"J. Physiol."},{"issue":"15","key":"10.1016\/j.cytogfr.2018.12.001_bib0900","doi-asserted-by":"crossref","first-page":"13357","DOI":"10.1074\/jbc.M110.214965","article-title":"Interleukin-13 (IL-13)\/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion","volume":"286","author":"Wu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0905","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1538\/expanim.63.133","article-title":"Overexpression of GATA-3 in T cells accelerates dextran sulfate sodium-induced colitis","volume":"63","author":"Okamora","year":"2014","journal-title":"Exp. Anim."},{"issue":"11","key":"10.1016\/j.cytogfr.2018.12.001_bib0910","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1136\/gutjnl-2016-313208","article-title":"Interleukin 13-mediated colitis in the absence of IL-4R\u03b1 signalling","volume":"66","author":"Hoving JC","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0915","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bcp.12589","article-title":"A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients","volume":"80","author":"Hua","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0920","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0925","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/imm.12319","article-title":"Therapeutic activity of an interleukin-4\/interleukin-13 dual antagonist on oxazolone-induced colitis in mice","volume":"143","author":"Kasaian","year":"2014","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0930","doi-asserted-by":"crossref","DOI":"10.4161\/19382014.2014.950547","article-title":"The impact of anti-inflammatory cytokines on the pancreatic beta-cell","volume":"6","author":"Russell","year":"2014","journal-title":"Islets"},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0935","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2337\/diabetes.48.8.1522","article-title":"Interleukin-13 prevents autoimmune diabetes in NOD mice","volume":"48","author":"Zaccone P","year":"1999","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0940","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaut.2009.08.004","article-title":"Association of T-cell reactivity with beta-cell function in recent onset type 1 diabetes patients","volume":"34","author":"Pfleger","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0945","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9391845","article-title":"Intralymphatic glutamic acid decarboxylase-alum administration induced Th2-like-specific immunomodulation in responder patients: a pilot clinical trial in type 1 diabetes","volume":"2018","author":"Tavira","year":"2018","journal-title":"J. Diabetes Res."},{"issue":"1-1","key":"10.1016\/j.cytogfr.2018.12.001_bib0950","first-page":"45","article-title":"General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes","volume":"75","author":"Ludvigsson","year":"2014","journal-title":"Pediatr. Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0955","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1365-3083.2000.00693.x","article-title":"In vitro interleukin-13 production by peripheral blood in patients with newly diagnosed insulin-dependent diabetes mellitus and their first degree relatives","volume":"51","author":"Kretowski A","year":"2000","journal-title":"Scand. J. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0960","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1086\/375655","article-title":"Association and interaction of the IL4R, IL4, and IL13 Loci with type 1 diabetes among Filipinos","volume":"72","author":"Bugawan","year":"2003","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib0965","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1086\/428387","article-title":"No evidence of Association or interaction between the IL4RA, IL4, and IL13 genes in type 1 diabetes","volume":"76","author":"Maier","year":"2005","journal-title":"Am. J. Hum. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.cytogfr.2018.12.001_bib0970","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1038\/gene.2009.96","article-title":"Analysis of 19 genes for association with type I diabetes in the type I diabetes genetics consortium families","volume":"10","author":"Howson","year":"2009","journal-title":"Genes Immun."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib0975","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaci.2005.12.1354","article-title":"Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes","volume":"117","author":"Maier","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib0980","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/gene.2009.89","article-title":"Association analysis of SNPs in the IL4R locus with type I diabetes","author":"Erlich","year":"2009","journal-title":"Genes Immun."},{"issue":"8","key":"10.1016\/j.cytogfr.2018.12.001_bib0985","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.2337\/diabetes.54.8.2482","article-title":"Association of non-HLA genes with type 1 diabetes autoimmunity","volume":"54","author":"Steck","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib0990","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.molmet.2015.11.003","article-title":"IL-13 improves beta-cell survival and protects against IL-1beta-induced beta-cell death","volume":"5","author":"Rutti","year":"2016","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib0995","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00125-018-4750-8","article-title":"The transcription factor STAT6 plays a critical role in promoting beta cell viability and is depleted in islets of individuals with type 1 diabetes","volume":"62","author":"Leslie","year":"2019","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib1000","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4049\/jimmunol.1700410","article-title":"On the role IL-4\/IL-13 heteroreceptor plays in regulation of type 1 diabetes","volume":"199","author":"Ukah","year":"2017","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.cytogfr.2018.12.001_bib1005","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1073\/pnas.230431397","article-title":"A targeted mutation in the IL-4Ralpha gene protects mice against autoimmune diabetes","volume":"97","author":"Radu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib1010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10753-011-9356-y","article-title":"Destruction of salivary and lacrimal glands by Th1-polarized reaction in a model of secondary Sjogren\u2019s syndrome in lupus-prone female NZB x NZWF(1) mice","volume":"35","author":"Hayashi","year":"2012","journal-title":"Inflammation"},{"issue":"5","key":"10.1016\/j.cytogfr.2018.12.001_bib1015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1136\/ard.2005.040956","article-title":"Th2 cytokine genotypes are associated with a milder form of primary Sjogren\u2019s syndrome","volume":"65","author":"Pertovaara","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib1020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cyto.2014.06.009","article-title":"Aberrant production of IL-13 by T cells promotes exocrinopathy in Id3 knockout mice","volume":"69","author":"Ian Belle","year":"2014","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib1025","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","article-title":"The Th1\/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren\u2019s syndrome","volume":"128","author":"Mitsias","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.cytogfr.2018.12.001_bib1030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0165-2478(95)02490-5","article-title":"Differential interleukin (IL)-10 and IL-13 gene expression in vivo in salivary glands and peripheral blood mononuclear cells from patients with primary Sj\u00f6gren\u2019s syndrome","volume":"49","author":"Villarreal","year":"1996","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.cytogfr.2018.12.001_bib1035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-015-0582-9","article-title":"Altered balance of interleukin-13\/interferon-gamma contributes to lacrimal gland destruction and secretory dysfunction in CD25 knockout model of Sjogren\u2019s syndrome","volume":"17","author":"Bian","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib1040","doi-asserted-by":"crossref","first-page":"R234","DOI":"10.1186\/ar4077","article-title":"Deletion of interferon-gamma delays onset and severity of dacryoadenitis in CD25KO mice","volume":"14","author":"Pelegrino","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.cytogfr.2018.12.001_bib1045","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1007\/s12325-017-0525-8","article-title":"RPC4046, A novel anti-interleukin-13 antibody, blocks IL-13 binding to IL-13 alpha1 and alpha2 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study","volume":"34","author":"Tripp","year":"2017","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib1050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000447692","article-title":"A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma","volume":"170","author":"Bagnasco","year":"2016","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2018.12.001_bib1055","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib1060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13543784.2018.1427729","article-title":"Targeted anti-IL-13 therapies in asthma: current data and future perspectives","volume":"27","author":"Ntontsi","year":"2018","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"9","key":"10.1016\/j.cytogfr.2018.12.001_bib1065","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"26","key":"10.1016\/j.cytogfr.2018.12.001_bib1070","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2018.12.001_bib1075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.5217\/ir.2018.16.2.233","article-title":"Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies","volume":"16","author":"Motoya","year":"2018","journal-title":"Intestinal Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2018.12.001_bib1080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib Ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2018.12.001_bib1085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/path.4733","article-title":"Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-gamma","volume":"239","author":"Ramalingam","year":"2016","journal-title":"J. Pathol."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610118301394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610118301394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:55:10Z","timestamp":1761216910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610118301394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":217,"alternative-id":["S1359610118301394"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2018.12.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-13: A promising therapeutic target for autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}